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ABSTRACT
Background: The Patient-Reported Indices for Multiple Sclerosis
(PRIMUS) comprises a suite of three scales for assessing symptoms, activ-
ity limitations, and quality of life in multiple sclerosis (MS). It was devel-
oped in the UK and has been shown to have excellent psychometric
properties. This study describes the adaptation of eight language versions
for Canadian English, Canadian French, French, German, Italian, Spanish,
Swedish, and US English.
Methods: The PRIMUS was translated using the dual-panel process. Cog-
nitive debrieﬁng interviews conducted with MS patients assessed face and
content validity. Psychometric and scaling properties were assessed via a
two-administration postal survey conducted in each country involving the
PRIMUS, the Nottingham Health Proﬁle (NHP), the Unidimensional
Fatigue Impact Scale (U-FIS), and demographic questions.
Results: Cognitive debrieﬁng interviews demonstrated the acceptability of
the new language versions. Analysis of survey data showed that the new
language versions of the three PRIMUS scales were unidimensional (as
indicated by ﬁt to the Rasch model) and that they had good internal
consistency and reproducibility. PRIMUS scale scores correlated as
expected with those on the NHP and the U-FIS. The scales in all countries
were able to discriminate between groups of patients on the basis of their
self-reported MS severity, general health, and employment status.
Conclusions: The PRIMUS was successfully adapted into eight new lan-
guages. Most of the tests showed the PRIMUS to have good unidimen-
sionality and to have good internal consistency, reproducibility, and
construct validity. The measure is now available for use in clinical studies
and trials involving these countries and the UK. Further work is required
to assess the measure’s responsiveness.
Keywords: activities, multiple sclerosis, patient-reported outcomes,
PRIMUS, quality of life, questionnaire; symptoms.
Introduction
Multiple sclerosis (MS) is a chronic, progressive, disabling
autoimmune disorder of the central nervous system that causes
inﬂammation and neurodegeneration [1]. It is one of the most
common neurological diseases affecting around 380,000 people
in Europe, up to 400,000 in the United States, and an estimated
2,500,000 people worldwide [2–4]. Age of onset is commonly
early to mid-adulthood [5]. In relapsing forms of MS patients
experience periods of relatively good health (remissions) alter-
nated with debilitating relapses. However, there is no set pattern,
and clinical manifestation will vary both between and within
patients depending on which areas of the central nervous system
are affected at any given point in time. Symptoms experienced
can include visual or sensory disturbances, loss of strength or
sensation in limbs, ambulatory problems, loss of bladder and
bowel control, cognitive impairment, fatigue, spasticity, and
sexual dysfunction. The disorder generally worsens over time,
leading to irreversible functional disability. Consequently, the
condition can have a profound impact on all aspects of the
patient’s life. Current treatment regimes aim at managing symp-
toms to maximize life quality or to impede disease progression.
However, the young age of onset means that the physical and
psychological effects may be apparent for much of the patient’s
adult life [5].
The variable and unpredictable nature of MS presents a chal-
lenge to patient-reported outcome (PRO) assessment. Generic
outcome measures will only assess some of the impacts of the
illness on the patient and will include questions on irrelevant
issues. Furthermore, the existing disease-speciﬁc measures fail to
address the full range of potential problems that MS patients
experience. The Patient-Reported Indices for Multiple Sclerosis
(PRIMUS) was developed in the UK to capture the overall impact
of MS from the patient’s perspective [6]. This instrument consists
of three distinct scales speciﬁc to MS: symptoms, activities, and
quality of life (QoL). Scale content was generated directly from
in-depth qualitative interviews with MS patients in the UK. Suf-
ﬁcient interviews were conducted to ensure that all relevant
issues were identiﬁed. Patients were then involved in each stage
of the scale development to ensure that items represented
patients’ own experience with MS.
As the PRIMUS was developed directly from patient inter-
views and is speciﬁc to their experience of MS, it ensures that all
relevant issues are assessed. Furthermore, as the PRIMUS con-
sists of unidimensional scales it provides a holistic assessment of
the impact of MS on patients. As there was a need to employ the
PRIMUS in an international clinical trial, additional language
versions of the measure were required. This paper reports on the
adaptation and validation of versions of the PRIMUS for Canada
(English and French), France, Germany, Italy, Spain, Sweden, and
the United States.
Methodology
Three stages were involved in the adaptations: translation,
assessment of face and content validity and formal psychometric
evaluation.
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Patients
Different patient samples were included at each of the three
stages of the study in each country. Participants were recruited
via patients’ organizations or clinics. When recruited from the
former source, potential participants were required to answer
screening questions to ensure that they were eligible for study
inclusion. Patients with signiﬁcant comorbidity that might inﬂu-
ence their responses to the questionnaire, such as diagnosed
psychiatric disorders or cancer, were excluded. All patients pro-
vided informed consent for their participation, and conﬁdential-
ity was maintained at each stage. Where patients were recruited
through clinical centers, ethical approval was obtained from the
relevant Research Ethics Board before the commencement of
study activities.
Translation
The adaptation of an instrument for use in another language
highlights a number of linguistic and conceptual issues. For
example, language contains many nuances and phrases that,
although well understood in the language in which the instru-
ment was developed, are not always clear to nonnative speakers.
Consequently, it is inappropriate to produce a new language
version of a questionnaire by simply translating the content
(literal translation). To produce new language versions that are
comparable across languages, it is necessary for items to have
conceptual equivalence. Conceptual equivalence ensures that the
meaning of the original item is preserved by the translation of the
concept or notion covered by that item.
The dual-panel translation methodology was used to produce
the new language versions of the PRIMUS [7]. The dual-panel
approach requires that the veriﬁcation and evaluation of accept-
ability of translations rests with people who are typical of the
patients who will later be asked to complete the questionnaire.
This approach aims to produce translated measures that use
clear, everyday language while maintaining conceptual equiva-
lence. The translation process was managed by the UK PRIMUS
developers who provided detailed item meanings for each scale
and worked closely with local investigators to ensure that the
conceptual meaning of items was retained in all countries. Trans-
lations were achieved via two translation panels (a “bilingual”
and a “lay” panel) conducted by the local investigators in each
country. The bilingual panel included a group of individuals
ﬂuent in both the target and source language. The panel worked
together as a group to agree on the most appropriate transla-
tions. The lay panel comprised a group of monolingual people of
average educational attainment. The remit of this group was to
consider the translations produced by the professional panel to
ensure that the questionnaire content was expressed in natural,
everyday language. As the PRIMUS was ﬁrst developed in UK
English the US- and Canadian-English translations required only
the lay panel. MS patients were excluded from both panels as the
purpose was to determine the most appropriate wording for the
PRIMUS rather than to comment on its content. All panels
consisted of between four and seven participants. At both stages
of the translation process, suggested changes to the translation
were agreed with the UK developers before continuation to the
next project stage.
Assessment of Face and Content Validity
Interviews were conducted with MS patients to test the accept-
ability, understanding, relevance, and comprehensiveness of the
new translations in each country. Participants were asked to
complete the PRIMUS in the presence of an interviewer who
noted any obvious difﬁculties. Participants were then invited to
comment on the questionnaire items, instructions, and response
format. In particular, they were asked to consider the acceptabil-
ity, clarity, and comprehensiveness of questionnaire content.
Scaling and Psychometric Evaluation
Psychometric surveys were conducted in each country. Partici-
pants completed the PRIMUS scales, the Unidimensional Fatigue
Impact Scale (U-FIS) [8,9], demographic questions, and items
about perceived MS severity and general health via postal survey
on two occasions, two weeks apart. Participants in all countries
other than Spain also completed the Nottingham Health Proﬁle
(NHP) [10,11].
Questionnaires. The development of the PRIMUS has been
described in detail previously [6]. It consists of three scales mea-
suring symptoms, activities, and QoL. Both the symptom and
QoL scale contain items in the form of simple statements accom-
panied by dichotomous response options. For each scale items
are summed to yield a total score ranging from 0 to 22. High
scores indicate worse symptomatic/QoL impact. The activities
scale contains 15 items describing speciﬁc tasks. Individuals rate
the degree to which they are able to perform the tasks on a
3-point scale. Again, items are summed to give a total score that
can range from 0 to 30. High scores are indicative of greater
levels of activity limitation.
The NHP is a measure of perceived distress that consists of
six sections: energy level, pain, physical mobility, sleep, social
interactions, and emotional reactions. Each section is scored 0 to
100 with a high score indicating greater distress. The U-FIS is a
new version of the Fatigue Impact Scale [12] that has been
developed to provide an index rather than a proﬁle of fatigue
impact scores. The U-FIS contains 22 items yielding a total score
that can range from 0 to 66. High scores are indicative of greater
impact of fatigue.
Patients also completed a demographic and disease question-
naire that included questions on self-rated MS severity (4-point
Likert scale from “mild” to “very severe”), self-perceived current
general health (4-point Likert scale from “very good” to
“poor”), employment status (working vs. unable to work), and
MS type.
Data analyses. Rasch analysis [13] was conducted on the data
from each country separately to determine scale unidimension-
ality using RUMM programme 2020 (RUMM Laboratory Pty
Ltd, Perth). The Rasch model was ﬁrst developed in the ﬁeld of
education and asserts that the easier an item is the more likely it
is to be afﬁrmed. According to the model the only two functions
governing whether a PRO item is afﬁrmed are the severity of the
item and the person’s level of the construct (for example, QoL)
being measured. Each item and person is placed in order of
severity based on item responses. Items that do not ﬁt the model
may be those that are answered inconsistently or where the
responses are inﬂuenced by factors other than that being mea-
sured by the scale. If items ﬁt the Rasch model then the scale as
a whole can be considered to be unidimensional and also meet
the strict properties of interval level measurement. Fit of the
PRIMUS scales was evaluated through chi-square ﬁt statistics. A
signiﬁcance level of 0.01 was chosen because of multiple-item
testing in each scale. Nonsigniﬁcant results would indicate that
the PRIMUS scales are unidimensional and that individual-item
scores could be summed to derive an overall scale score. Rasch
analysis was also used to determine whether external factors
inﬂuenced scores via differential item functioning (DIF). DIF is an
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additional aspect of model ﬁt and occurs when subgroups of
individuals respond systematically differently to items, thus
having the potential to produce bias within the scale [14]. Age
and gender were assessed for DIF in the present analyses. Con-
sistency in item ordering was also investigated in each country to
assess cross-cultural equivalence of the scales. If item ordering is
similar across the language adaptations then this presents pre-
liminary evidence of the cross-cultural equivalence of the scales.
Bonferroni corrections were applied to both item ﬁt and DIF
analyses because of the large number of analyses performed.
Internal consistency (the degree of relatedness of items) was
assessed by Cronbach’s alpha coefﬁcients for each scale. A value
of 0.70 or above was taken as being indicative of adequate
internal consistency [15]. Reliability of the new PRIMUS scales
(an estimate of the instrument’s reproducibility over time,
assuming that no change in condition has taken place) was
assessed using Spearman’s rank test–retest and intraclass corre-
lation (ICC). A high correlation (above 0.85) indicates that the
scale produces very low levels of random measurement error
[16].
Convergent and divergent validity were evaluated by assess-
ing the level of association (Spearman rank correlations) between
scores on the PRIMUS scales and those on the U-FIS and NHP
section scores. Moderate correlations were anticipated between
the scales, indicating that they assess different but related con-
structs. Known Groups validity was assessed by examining the
PRIMUS scores of respondents who differed according to their
self-perceived MS severity, self-perceived current general health,
and employment status. Individuals with worse general health
and severity were expected to have signiﬁcantly higher PRIMUS
scores. Individuals unable to work were expected to have signiﬁ-
cantly worse PRIMUS scores. Nonparametric tests for indepen-
dent samples (Mann-Whitney U-test for two groups and
Kruskal-Wallis Test for three or more groups) were employed to
test for differences. Psychometric testing was completed using the
SPSS 15.0 statistical package (SPSS, Chicago, IL).
Results
Translation
The PRIMUS was successfully translated in all countries. The lay
panels employed for the non-English translations suggested
improvements to some items provided by the professional panel
that improved item clarity or immediacy.
Cognitive Debrieﬁng Interviews
Interviewee details are shown in Table 1. All participants were
able to respond to all items. Participants reported that the items
were easy to understand and relevant to someone with MS—even
those symptoms that did not currently apply to them. No areas
were consistently reported to be missing from the questionnaire,
and no items were reported to be redundant to patients. No
changes in wording were required as a result of the patient
interviews in any country.
Psychometric and Scaling Postal Surveys
Participant’s details and the total number of patients included in
each language adaptation are shown in Table 1. Throughout the
psychometric analysis, if individuals had missing data for a given
test they were not included in the analysis for that test. Many
participants were unaware of their type of MS. Of those who
were able to report the type, 55.5% were relapse remitting, 14%
primary progressive, 21.7% secondary progressive, 5.1% pro-
gressive relapsing, and 8.9% benign.
PRIMUS scaling properties. The ﬁt of the PRIMUS scales to the
Rasch model is shown in Table 2. For the Symptoms scale, ﬁt was
demonstrated for all language versions. The Spanish version of
the activity limitations scale showed borderline misﬁt to the
model. The overall ﬁt statistics for the QoL scale showed that all
language adaptations except the French version ﬁt the Rasch
model.
DIF was minimal for all language versions of the PRIMUS
scales. After applying Bonferroni corrections to symptoms scale
data, minimal DIF was observed by age for one item on the
Canadian-French adaptation and by gender for two items on the
Swedish version. None of the items in the QoL scale exhibited
DIF.
Table 3 shows the three consistently mildest (representing the
least symptomatic/activity limitation or QoL impact) and three
consistently severest (representing the greatest symptomatic/
activity limitation or QoL impact) items across all eight countries
as identiﬁed by Rasch analysis.
Table 1 Demographic details of participants
Country C-E C-F F D I E Sw US-E
Cognitive debrieﬁng
N 15 15 9 15 15 11 14 15
Female n (%) 13 (86.7) 11 (73.3) 5 (55.6) 9 (60.0) 11 (73.3) 5 (45.5) 8 (57.1) 11 (73.3)
Age (years) mean (SD) 42.8 (12.9) 39.2 (15.8) 39.0 (12.9) 42.9 (13.4) 51.7 (12.9) 48.9 (8.3) 47.8 (11.5) 54.3 (5.9)
MS duration (years) mean (SD) 8.7 (6.9) 11.8 (10.0) 12.0 (9.2) 8.4 (11.6) 19.7 (12.3) 19.5 (10.4) 12.4 (6.5) 22.7 (13.7)
Postal survey
N 96 102 85 76 100 87 167 104
Female n (%) 71 (74.0) 56 (64.4) 48 (56.5) 54 (71.1) 65 (65.0) 56 (64.4) 102 (61.1) 85 (81.7)
Age (years) mean (sd) 44.5 (9.9) 45.1 (10.5) 48.5 (10.4) 42.1 (12.3) 53.1 (12.1) 43.6 (11.0) 48.7 (12.1) 45.7 (10.8)
Type of MS n (%)
Relapse remitting 70 (72.9) 39 (38.2) 12 (14.1) 40 (52.6) 17 (17.0) 41 (47.1) 47 (23.5) 82 (78.8)
Primary progressive 4 (4.2) 7 (6.9) 17 (20) 7 (9.2) 29 (29.0) 6 (6.9) 14 (7.0) 4 (3.8)
Secondary progressive 5 (5.2) 19 (18.6) 23 (27.1) 9 (11.8) 29 (29.0) 16 (18.4) 25 (12.5) 10 (9.6)
Progressive relapsing 3 (3.1) 0 6 (7.1) 2 (2.6) 11 (11.0) 2 (2.3) 6 (3.0) 2 (1.9)
Benign 10 (10.4) 8 (7.8) 2 (2.4) 2 (2.6) 4 (4.0) 21 (24.1) 7 (3.5) 2 (1.9)
Not reported 4 (2.2) 29 (28.4) 25 (29.4) 16 (21.1) 10 (10.0) 1 (1.1) 101 (50.5) 4 (3.8)
MS duration (years) mean (sd) 11.6 (8.5) 10.4 (7.5) 15.3 (9.4) 8.8 (8.0) 17.8 (10.8) 9 (7.3) 15.4 (10.1) 10.1 (8.9)
C-E, Canada (English); C-F, Canada (French); D, Germany; E, Spain; F, France; I, Italy; Sw, Sweden; US-E, US English; MS, multiple sclerosis.
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Traditional psychometric properties.
Internal consistency. Cronbach’s alpha coefﬁcients were in
excess of the minimum requirement of 0.70 for all three PRIMUS
scales in all eight languages (Table 4). This conﬁrms that the
items in the scales are adequately related to each other.
Test–retest reliability. For the activity limitations and QoL scales
all test–retest and ICCs were 0.85 or above, indicating that they
had excellent reproducibility and that the scales can be used on an
individual basis in clinical practice and also as outcome measures
in clinical studies and trials. For Symptoms test–retest and ICCs
were slightly lower, but most achieved a level of 0.80 (Table 4).
Convergent validity. Table 5 shows the correlations between the
PRIMUS scales and the U-FIS and NHP. The PRIMUS symptoms
scale correlated highest with the U-FIS and the NHP energy level,
pain, and physical mobility sections reﬂecting the importance of
these outcomes in MS symptomatology. The activity limitations
scale correlated highest with the NHP Physical Mobility scale as
expected and moderately with U-FIS. Again, as expected, there
was a lower association between PRIMUS activities and the
emotional reactions and sleep sections of the NHP. The QoL
scale correlated highest with U-FIS and the energy level, emo-
tional reactions, and social isolation sections of the NHP.
PRIMUS QoL correlated moderately highly with the other NHP
sections, suggesting that it is providing an overall assessment of
the impact of MS on patients.
Known groups validity. Table 6 shows PRIMUS scale scores by
known factors. All three PRIMUS scales were able to distinguish
between groups of patients categorized by self-perceived MS
severity, general health, and employment status. Differences in
scales scores were statistically signiﬁcant for all countries except
France. Results showed that mean scores for each scale were
higher (indicating poorer symptom/activity/QoL status) in the
groups with worse self-perceived severity and general health.
Similarly, working patients had consistently milder scores on the
three scales. The French symptoms and QoL scales showed
similar trends that did not reach statistical signiﬁcance.
Table 2 Overall Rasch chi-square ﬁt statistics of the PRIMUS
PRIMUS scale C-E C-F F D I E Sw US-E
Symptoms (n) 98 83 83 65 92 71 145 98
P-value 0.44 0.22 0.14 0.20 0.41 0.18 0.72 0.50
Activity limitations (n) 66 79 80 55 80 61 124 81
P-value 0.47 0.37 0.05 0.26 0.88 0.01 0.10 0.59
QoL (n) 93 94 83 67 99 84 160 102
P-value 0.73 0.73 0.00 0.21 0.54 0.96 0.43 0.59
C-E, Canada (English); C-F, Canada (French); D, Germany; E, Spain; F, France; I, Italy; Sw, Sweden; US-E, US English; PRIMUS, Patient-Reported Indices for Multiple Sclerosis; QoL, quality of life.
Table 3 PRIMUS item ordering
Symptoms
Mildest items
Have you experienced weakness in your arms or legs?
Have you had problems with your balance?
Have you been forgetting things?
Most severe items
Have you had difﬁculty swallowing?
Have you had bowel incontinence?
Have you experienced paralysis in any part of your body?
Activity limitations
Mildest items




Have an allover wash (including bath or shower)




I have to pace myself throughout the day
I have to push myself to do things
My self-conﬁdence is affected
Most severe items
I can’t think about anything but the MS
I’m neglecting my appearance
I feel as if I have nothing to offer anyone
PRIMUS, Patient-Reported Indices for Multiple Sclerosis; QoL, quality of life.
Table 4 Internal consistency and test–retest reliability of the new language versions of the PRIMUS scales
PRIMUS scale C-E C-F F D I E Sw US-E
Symptoms
Cronbach’s alpha 0.86 0.81 0.82 0.87 0.76 0.87 0.84 0.80
Test–retest reliability 0.88 0.83 0.79 0.93 0.78 0.81 0.84 0.84
ICC 0.86 0.86 0.82 0.93 0.81 0.80 0.84 0.84
Activity limitations
Cronbach’s alpha 0.94 0.96 0.94 0.96 0.96 0.97 0.97 0.96
Test–retest reliability 0.94 0.97 0.93 0.93 0.97 0.87 0.94 0.94
ICC 0.91 0.98 0.94 0.90 0.97 0.88 0.96 0.95
QoL
Cronbach’s alpha 0.90 0.94 0.96 0.89 0.90 0.88 0.89 0.90
Test–retest reliability 0.90 0.92 0.90 0.91 0.93 0.86 0.91 0.92
ICC 0.92 0.91 0.91 0.89 0.85 0.90 0.91 0.93
All correlations are signiﬁcant at the 0.01 level (two-tailed).
C-E, Canada (English); C-F, Canada (French); D, Germany; E, Spain; F, France; I, Italy; Sw, Sweden; US-E, US English; ICC, intraclass correlation; PRIMUS, Patient-Reported Indices for Multiple
Sclerosis; QoL, quality of life.
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Discussion
The variable and unpredictable nature of MS has presented a
challenge to the assessment of PROs. The PRIMUS was developed
to provide an empirical assessment of patient’s perception of the
symptomatic, activity limitation, and QoL beneﬁts of treatment.
The UK version of the measure has been shown to be well
accepted by patients and to have good psychometric properties.
The present study describes the adaptation and validation of new
language versions of the PRIMUS scales. Additional language
versions of the scales were required to allow the PRIMUS to be
used in international clinical trials of treatments for MS. A well-
established adaptation methodology was applied to ensure that
the new language versions were conceptually equivalent to the UK
original scales and that they would have equally acceptable psy-
chometric qualities. Large samples of MS patients were employed
to determine the internal consistency, reproducibility, and con-
struct validity of the new language versions.
The evidence presented supports the quality of the new lan-
guage versions of the PRIMUS scales. Application of the Rasch
model showed all but two of the PRIMUS scales to be unidimen-
sional using Time 1 data. Adaptations were shown to have good
item stability and minimal DIF. Conﬁrmation of unidimension-
ality means the scales are capable of providing single indices of
symptomatic, activity, and QoL impact that are easy to interpret.
In addition, the examination of item severity across countries
indicated that item ordering at the extremes is very similar. This
suggests that the relative severity of the items has been retained in
each country after the translation process.
Each new PRIMUS scale demonstrated high internal consis-
tency. All scales showed good ICC and test-retest reliability indi-
cating that there are low levels of random error inherent in the
scales. The symptoms scale had lower ICC and test-retest scores
than the QoL and activity limitations scales. However, this may
be expected as symptoms are more variable on a day to day basis
than activity limitation or QoL. Evidence of construct validity
was provided by consistent correlations with comparator mea-
sures and by the ability of the scales to distinguish between
groups of patients categorised by known factors.
The study has a number of limitations. Two of the twenty-
four scale adaptations showed some level of misﬁt to the Rasch
model. However, no allowance was made for multiple testing in
the analyses. Further research is needed to conﬁrm the unidimen-
sionality of these two scales. In addition, the French QoL and
Activities scales failed to distinguish between participants based
on self-perceived MS severity. Further evidence of the construct
validity for these two scales is desirable. The design of the study
did not allow for an assessment of the responsiveness of the
different language versions of the PRIMUS or the meaningfulness
of change scores. Additional research is required to determine
these properties. Furthermore, the current study did not allow
the comparison of PRIMUS scores with clinical markers of MS or
the comparison of PRIMUS scores between MS types.
Conclusions
It is concluded that the PRIMUS scales were successfully trans-
lated into eight new languages. Evidence indicated that there
were few problems with the psychometric and scaling properties
of the new language versions developed. The PRIMUS validly
and reliably provides an empirical assessment of patient percep-
tions of the symptomatic, activity limitation, and QoL beneﬁts of
treatment.
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Table 5 Convergent validity of the new language versions of the PRIMUS activity scale with U-FIS and the NHP
PRIMUS scale C-E C-F F D I E Sw US-E
Symptoms
U-FIS 0.76 0.69 0.58 0.83 0.71 0.77 0.70 0.69
NHP energy level 0.73 0.63 0.40 0.74 0.47 N/A 0.63 0.53
Pain 0.70 0.62 0.71 0.55 0.51 0.56 0.62
Emotional reactions 0.57 0.21 0.45 0.55 0.40 0.54 0.48
Sleep 0.43 0.39 0.36 0.43 0.33 0.39 0.44
Physical mobility 0.67 0.61 0.24 0.67 0.50 0.51 0.57
Social isolation 0.44 0.26 0.23* 0.44 0.29 0.45 0.50
Activity limitations
U-FIS 0.65 0.54 0.28 0.65 0.45 0.58 0.44 0.62
NHP energy level 0.72 0.50 0.33 0.58 0.27 N/A 0.53 0.59
Pain 0.56 0.50 0.35 0.39 0.27 0.44 0.61
Emotional reactions 0.23 0.23 0.22* 0.15* 0.22 0.19 0.21
Sleep 0.30 0.21 0.09* 0.22* 0.25 0.18 0.22
Physical mobility 0.88 0.91 0.85 0.82 0.79 0.89 0.89
Social isolation 0.44 0.33 0.31 0.36 0.24 0.44 0.41
QoL
U-FIS 0.81 0.79 0.69 0.80 0.67 0.84 0.79 0.73
NHP energy level 0.73 0.68 0.26 0.79 0.45 N/A 0.73 0.63
Pain 0.47 0.41 0.26 0.50 0.18* 0.45 0.50
Emotional reactions 0.63 0.58 0.64 0.61 0.71 0.68 0.58
Sleep 0.37 0.30 0.21* 0.38 0.30 0.27 0.41
Physical mobility 0.61 0.58 0.30 0.60 0.49 0.61 0.63
Social isolation 0.68 0.65 0.75 0.74 0.64 0.70 0.68
All correlations are signiﬁcant at the 0.05 level (2-tailed) except where marked with a *.
C-E, Canada (English); C-F, Canada (French); D, Germany; E, Spain; F, France; I, Italy; Sw, Sweden; US-E, US English; NHP, Nottingham Health Proﬁle; PRIMUS, Patient-Reported Indices for Multiple
Sclerosis; QoL, quality of life; U-FIS, Unidimensional Fatigue Impact Scale.
950 McKenna et al.
References
1 Mohr DC, Pelletier D. A temporal framework for under-
standing the effects of stressful life events on inﬂammation in
patients with multiple sclerosis. Brain Behav Immun 2005;12:1–
10.
2 Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. Cost of disor-
ders of the brain in Europe. Eur J Neurol 2005;12(Suppl. 1):1–27.
3 Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology
and estimated population burden of selected autoimmune dis-
eases in the United States. Clin Immunol Immunopathol
1997;84:223–43.
4 Cooper GS, Stroehla BC. The epidemiology of autoimmune
diseases. Autoimmun Rev 2003;2:119–25.
5 Johnson KL, Amtmann D, Yorkston K, et al. Medical,
psychological, social, and programmatic barriers to employ-
ment for people with multiple sclerosis. J Rehabil 2004;70:38–
49.
6 Doward LC, McKenna SP, Meads DM, et al. The development of
Patient Reported Outcome Indices for Multiple Sclerosis
(PRIMUS). Mult Scler 2009;15:1092–102.
7 Swaine-Verdier A, Doward LC, Hagell P, et al. Adapting
quality of life instruments. Value Health 2004;7(Suppl.):S27–
30.
8 Meads DM, Doward LC, McKenna SP, et al. The development
and validation of the Unidimensional Fatigue Impact Scale
(U-FIS). Mult Scler 2009;15:1228–38.
9 Doward LC, Meads DM, Fisk J, et al. International development
of the Unidimensional Fatigue Impact Scale (U-FIS). Value Health
11 March 2010 [Epub ahead of print].
10 Hunt SM, McEwen J, McKenna SP. Measuring Health Status.
London: Croom Helm, 1986.
11 European Group for Quality of Life Assessment and Health Mea-
surement. European Guide to the Nottingham Health Proﬁle.
Brookwood, Surrey: Brookwood Medical Publications, 1993.
12 Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact
of fatigue: initial validation of the fatigue impact scale. Clin Infect
Dis 1994;18(Suppl. 1):S79–83.
13 Rasch G. Probabilistic Models for Some Intelligence and
Attainment Tests. Copenhagen: Danish Institute for Educational
Research, 1960. (Expanded edition, Chicago: The University of
Chicago Press, 1980).
14 Holland PW, Wainer H, eds. Differential Item Functioning. New
Jersey: Lawrence Erlbaum Associates, 1993.
15 Nunally JC Jr. Psychometric Theory (2nd ed.). New York:
McGraw-Hill, 1978.
16 Streiner D, Norman G. Health Measurement Scales. Oxford:
Oxford University Press, 1989.
Table 6 Known Groups validity of the new language versions of the PRIMUS scales
Mean PRIMUS scale score
C-E C-F F D I E Sw US-E
Symptoms
Employment; mean (SD)
Working 6.6 (5.0) 5.3 (4.0) 9.0 (4.7) 5.6 (4.2) 6.5 (3.7) 5.7 (4.4) 6.6 (5.0) 9.6 (4.4)
Not working because of MS 9.5 (4.6) 8.8 (3.5) 10.6 (4.8) 8.9 (5.0) 9.2 (4.3) 9.7 (5.1) 9.7 (4.2) 12.8 (3.3)
P <0.01 <0.01 0.18 <0.05 <0.05 <0.01 <0.01 <0.01
Perceived MS severity; mean (SD)
Mild 6.1 (4.6) 4.7 (3.4) 7.5 (2.2) 3.0 (3.5) 5.5 (3.8) 4.4 (3.3) 4.9 (3.8) 8.1 (4.2)
Moderate 10.5 (4.5) 8.5 (3.7) 9.7 (5.0) 7.5 (4.2) 7.9 (3.5) 10.7 (4.6) 8.9 (4.3) 12.5 (3.7)
Quite/very severe 11.8 (3.8) 10.2 (4.0) 10.8 (4.2) 11.8 (4.3) 10.0 (4.0) 7.6 (5.6) 12.0 (4.0) 13.3 (2.4)
P <0.01 <0.01 0.18 <0.01 <0.01 <0.01 <0.01 <0.01
Perceived general health; mean (SD)
Good/very good 6.1 (4.3) 5.8 (3.7) 7.8 (3.1) 4.2 (4.3) 6.3 (4.2) 4.5 (3.8) 5.2 (3.9) 8.8 (4.1)
Fair/poor 11.7 (4.3) 9.4 (4.0) 11.2 (4.6) 9.4 (4.2) 9.3 (3.7) 10.1 (4.7) 10.5 (3.9) 13.8 (3.0)
P <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Activity limitations
Employment; mean (SD)
Working 3.1 (4.4) 3.3 (4.5) 8.9 (5.9) 2.3 (3.0) 6.5 (6.3) 4.0 (7.1) 3.6 (5.6) 4.3 (5.6)
Not working because of MS 9.4 (7.4) 11.6 (7.9) 15.5 (7.5) 12.8 (10.1) 22.3 (8.1) 15.2 (8.6) 14.3 (9.1) 13.1 (8.2)
P <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Perceived MS severity; mean (SD)
Mild 2.8 (4.0) 1.7 (2.4) 4.7 (6.0) 1.1 (1.9) 11.1 (10.5) 2.8 (6.0) 3.7 (7.2) 2.8 (4.6)
Moderate 9.7 (7.2) 9.7 (5.9) 10.3 (6.1) 8.3 (7.1) 15.3 (9.5) 12.0 (8.9) 8.9 (7.9) 11.2 (7.9)
Quite/very severe 14.5 (6.4) 18.1 (7.7) 18.3 (6.2) 16.7 (9.6) 22.7 (7.4) 17.9 (8.9) 16.7 (8.8) 16.4 (7.6)
P <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
Perceived general health; mean (SD)
Good/very good 3.9 (5.8) 4.4 (5.9) 8.1 (7.9) 3.7 (6.2) 15.1 (10.6) 4.9 (8.9) 4.9 (7.9) 5.2 (6.2)
Fair/poor 9.4 (6.3) 13.6 (7.2) 15.4 (6.0) 11.2 (8.9) 19.5 (9.0) 12.2 (8.5) 11.4 (8.9) 12.9 (8.6)
P <0.01 <0.01 <0.01 <0.01 <0.05 <0.01 <0.01 <0.01
QoL
Employment; mean (SD)
Working 4.0 (4.0) 3.4 (3.9) 8.5 (5.8) 5.5 (5.9) 7.1 (5.4) 4.7 (5.1) 4.3 (4.5) 6.3 (5.1)
Not working because of MS 9.0 (5.5) 8.6 (5.2) 10.7 (5.5) 7.7 (4.2) 10.7 (4.8) 11.0 (6.3) 8.4 (5.3) 11.2 (4.9)
P <0.01 <0.01 0.16 <0.05 <0.05 <0.01 <0.01 <0.01
Perceived MS severity; mean (SD)
Mild 4.4 (4.5) 2.5 (2.7) 6.8 (5.8) 2.8 (3.4) 4.6 (5.6) 3.0 (3.6) 2.8 (3.3) 4.7 (3.8)
Moderate 8.1 (4.9) 7.8 (4.8) 8.8 (5.2) 6.2 (4.2) 8.7 (5.0) 10.9 (6.4) 7.0 (4.8) 10.5 (5.3)
Quite/very severe 12.8 (5.4) 11.1 (5.7) 11.0 (5.4) 11.6 (3.5) 11.8 (4.8) 10.2 (6.6) 11.2 (5.1) 14.5 (4.2)
P <0.01 <0.01 0.11 <0.01 <0.01 <0.01 <0.01 <0.01
Perceived general health; mean (SD)
Good/very good 4.7 (4.6) 4.0 (3.9) 6.4 (4.0) 3.3 (3.2) 6.9 (4.8) 3.4 (4.4) 2.8 (3.5) 6.2 (5.0)
Fair/poor 9.7 (4.8) 9.8 (5.4) 11.1 (5.3) 8.9 (4.8) 10.8 (5.4) 11.2 (5.9) 9.1 (4.7) 11.8 (5.0)
P <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
C-E, Canada (English); C-F, Canada (French); D, Germany; E, Spain; F, France; I, Italy; Sw, Sweden; US-E, US English; PRIMUS, Patient-Reported Indices for Multiple Sclerosis; QoL, quality of life.
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